Core Viewpoint - The A-share market has shown active trading with significant focus on sectors like chemicals and non-ferrous metals, driven by price increases and strong performance in ETFs related to these sectors [1][2]. Group 1: Market Performance - The A-share market closed February with the Shanghai Composite Index achieving three consecutive monthly gains, with daily trading volumes exceeding 1 trillion yuan becoming a norm [1]. - On February 27, the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1]. - Over 3,200 stocks in the market saw gains, with notable performances in small metals and rare earths, leading to a surge in stocks like Hunan Gold [1]. Group 2: Sector Highlights - The non-ferrous metals sector continued to perform strongly, with the non-ferrous ETF (159876) reaching a peak increase of 3.82% and closing up 3.74% on the day [4]. - The chemical sector benefited from rising prices, with the chemical ETF (516020) achieving four consecutive daily gains, marking its highest point since January 2022 [1][4]. - The AI sector is gaining traction, with domestic AI usage surpassing that of the US, benefiting the domestic AI industry chain, as reflected in the performance of the innovation-focused AI ETF (589520) [1]. Group 3: ETF Performance - The electric power ETF (159146) saw a significant increase of 2.64%, reaching a new high since its listing, driven by the rising demand for electricity due to AI development [2][10]. - The largest medical ETF (512170) in the market rose by 1.14%, recovering its annual line, with a net inflow of over 1.9 billion yuan in the previous three days [14][16]. - The electric power sector is viewed as a defensive investment amid the AI boom, with the electric power ETF focusing on various energy sources including thermal, hydro, wind, nuclear, and solar power [12]. Group 4: Future Outlook - Analysts suggest that the non-ferrous metals sector still has upward momentum, supported by supply disruptions and high demand, with a focus on precious, industrial, battery, and strategic metals [7]. - The medical sector is expected to recover, with growth opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI in healthcare [16][18].

Core Insights - The healthcare sector in Hong Kong is experiencing significant growth opportunities driven by advancements in brain-computer interfaces, AI healthcare, and CXO services [2][18]. Group 1: Brain-Computer Interfaces - Neuralink, a company owned by Elon Musk, has commenced mass production, indicating a strong push in brain technology [2][18]. - Strong Brain Technology has completed a financing round of 2 billion yuan and is preparing for an IPO [2][18]. Group 2: AI Healthcare - Major AI companies are entering the healthcare space, with Alibaba launching "Ant Aifu" and OpenAI introducing ChatGPT Health [3][18]. Group 3: CXO Services - Companies such as WuXi AppTec, Tigermed, and Zhaoyan New Drug are forecasting net profits exceeding 100% for 2025, indicating positive performance expectations in the CXO sector [4][18]. Group 4: Market Performance - The healthcare index has shown high elasticity and volatility, with a maximum increase of 148.52% during the last pharmaceutical bull market, significantly outperforming comparable indices [8][22]. - The maximum decline since 2021 for the healthcare index was -80.73%, while the cumulative return since inception is -0.93% [10][24]. Group 5: Investment Opportunities - The Hong Kong Stock Connect Medical ETF provides a streamlined way to invest in leading healthcare companies in Hong Kong [20]. - The healthcare sector is characterized by high volatility, making it an attractive option for investors looking for significant returns [8][22].

Market Overview - The Hong Kong stock market experienced a broad adjustment on January 19, with the Hang Seng Index falling nearly 1% and the pharmaceutical sector declining alongside the market [1] - The Hong Kong Stock Connect Medical ETF, Huabao (159137), saw a drop of 2%, frequently trading at a premium, while major stocks like WuXi Biologics fell over 5% [1][2] - AI healthcare leaders JD Health and Alibaba Health both dropped more than 1% [1] Pharmaceutical Sector Performance - The medical sector opened lower and continued to decline, with the Hong Kong Stock Connect Innovation Drug ETF (520880) dropping over 2% during the session [1] - Key stocks in the innovation drug sector, such as BeiGene and CanSino Biologics, also fell by more than 2%, while several others, including China Biologic Products and 3SBio, dropped over 4% [1] Trading Activity - The Hong Kong Stock Connect Innovation Drug ETF (520880) was noted for its persistent premium trading, indicating strong buying interest, with a transaction volume exceeding 200 million yuan [3] - The ETF's price was reported at 0.541, down 1.99%, with a trading volume of 4.65 billion [4] Future Outlook - The National Medical Products Administration of China announced that by 2025, 76 innovative drugs are expected to be approved, placing China at the forefront globally [4] - The total transaction volume for overseas licensing of Chinese innovative drugs is projected to exceed 130 billion USD in the same year [4] - Analysts believe that the Chinese innovative drug sector is entering a phase of simultaneous benefits from "going global, technology, and policy," leading to a revaluation of innovative drug stocks [5] Investment Opportunities - Starting in January 2026, several innovative drug companies will release their earnings forecasts for 2025, presenting potential valuation recovery opportunities for those exceeding expectations [6] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovation Drug Select Index, which has distinct advantages, including a focus on pure innovative drug companies and a significant weighting of leading firms [6][7] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the sector [7]